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Abstract
Background: Synucleinopathies comprise a group of neurodegenerative diseases associated with abnormal
accumulation of α-synuclein. One of the key factors that contribute to the progression of synucleinopathies is
neuroinflammation. However, the role of lymphocytes in synucleinopathies like Parkinson’s disease (PD) remains
largely unclear.
Methods: To investigate how lymphocytes impact synucleinopathies, human wild-type α-synuclein (WTS) transgenic
mice were crossed with mice lacking mature lymphocytes (Rag2−/−). In this in vivo model, we quantified α-synuclein
aggregation in the substantia nigra (SN) and striatum and determined the numbers of innate and adaptive immune
cells in the central nervous system (CNS). The activation state of resident and infiltrated CNS myeloid cells (M1 vs. M2)
was further classified by gene and protein expression analyses. The impact of T and B lymphocytes on the phagocytic
activity of microglia in the presence of α-synuclein aggregates was addressed in BV2 microglia in vitro.
Results: Compared to WTS+ Rag2+/+ mice, where T but not B lymphocytes infiltrated the CNS, decreased amounts of
α-synuclein aggregates were found in WTS+ Rag2−/− mice devoid of mature lymphocytes. The presence of T lymphocytes
did not alter the number of Iba1+ microglia but increased the frequency of the CD11b+ CD45hi population in the CNS,
indicative of an increased number of infiltrated macrophages. Moreover, the M1 phenotype was more prominent in
WTS+ Rag2+/+ mice, whereas the M2 activation state was dominating in the absence of lymphocytes in WTS+ Rag2−/−
mice. In vitro, in the presence of T but not B lymphocytes, significantly less α-synuclein was phagocytosed by BV2
microglia, further supporting the prevalence of the M1 phenotype in the presence of T lymphocytes.
Conclusions: Peripheral T lymphocytes strongly contribute to increased α-synuclein pathology via modulation of CNS
myeloid cell function. In the presence of T lymphocytes, microglia phagocytosis of aggregated α-synuclein is reduced,
which increases the severity of synucleinopathy.
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Background
Synucleinopathies comprise a group of neurodegener-
ative diseases characterized by abnormal deposition of
α-synuclein in neurons and glia. The most frequent
synucleinopathy is Parkinson’s disease (PD), in which
α-synuclein pathology propagates throughout the
brain as clinical symptoms progress [1]. Possible
pathological mechanisms resulting in α-synuclein
aggregation and neurodegeneration in sporadic PD
are environmental factors, mitochondrial dysfunction,
oxidative stress, and neuroinflammation [2, 3]; how-
ever, the exact mechanism of α-synuclein aggregation
remains elusive.
Myeloid cells collectively describe cells derived from
the bone marrow, including granulocytes and monocytes
[4]. In the central nervous system (CNS), several
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myeloid populations are present including microglia and
macrophages (in further termed CNS myeloid cells) [5].
Upon activation, in response to brain injuries or to
immunological stimuli [6, 7], CNS myeloid cells undergo
morphologic alterations from resting ramified CNS mye-
loid cells into activated amoeboid CNS myeloid cells.
Activated CNS myeloid cells are further divided into
classical activation (M1 phenotype), characterized by
expression of pro-inflammatory genes (e.g., TNF-α,
IL-1β, and ICAM), or alternative activation (M2
phenotype), indicating an anti-inflammatory phago-
cytic phenotype, expressing characteristic phagocytic
and anti-inflammatory genes (e.g., Arg1, Lgals3, and
CD200r), analogous to peripheral myeloid cells. The
M2 phenotype is involved in debris clearance [8–11] and
was shown to decrease pathology in multiple sclerosis
(MS) and amyloid beta deposits in Alzheimer’s disease
[12]. In PD, activated microglia and pro-inflammatory
cytokine production were evident in human post mortem
brains and animal models [13–16], although the modula-
tion of myeloid cell activation in PD is not yet fully
understood.
Besides activation of myeloid cells [17], there are indica-
tions that the adaptive immune response is also involved
in PD-associated disease progression [18, 19]. A genome-
wide association study (GWAS) linked sporadic PD with
polymorphisms in the human leukocyte antigen (HLA)
region, a locus of genes encoding for surface proteins,
expressed by activated antigen presenting cells, including
microglia in the brain, and interacting with T cell recep-
tors [20]. Alterations in lymphocyte populations were de-
termined in the peripheral blood of PD patients [17, 21].
Furthermore, T lymphocytes were shown to infiltrate the
brain of PD patients and to mediate dopaminergic (DA)
neuronal loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydro-
pyridine (MPTP) mouse model of PD [18]. The MPTP
model is characterized by acute DA neuronal loss. Besides
neuronal loss, continuous aggregation of α-synuclein is
the major hallmark of PD pathology, preceding neuronal
loss. Therefore, transgenic animal models over-expressing
α-synuclein will specifically allow deciphering, whether
and how adaptive immune cells are involved in the
early pathological mechanism of disease progression
in synucleinopathies.
Accordingly, we asked, what is the impact of lymphocytes
in a mouse model for synucleinopathies over-expressing
human wild-type α-synuclein (WTS) under the murine
Thy1 (mThy1) promoter [22]. Therefore, we crossed
mThy1 WTS mice (WTS+) with mice containing a deletion
of the Rag2 gene (Rag2−/−), which lack mature lymphocytes
[23]. We demonstrate that infiltration of T lymphocytes
into the CNS of WTS+ Rag2+/+ mice increased α-synuclein
pathology in the substantia nigra (SN) and striatum, while
no B cells were found. The presence of T cells in WTS+
Rag2+/+ mice was strongly associated with increased levels
of pro-inflammatory mediators and the M1 phenotype. In
the absence of T cells, increased expression of M2 defining
markers and higher frequencies of infiltrating macrophages
(CD11b+ CD45hi) were found in the CNS, which could
contribute to the decreased levels of α-synuclein aggregates
in WTS+ Rag2−/− mice due to increased phagocytic activity.
Conversely, B cells did not affect phagocytosis activity of
myeloid cells in vitro.
Our data indicate that T lymphocytes aggravate the
aggregation of α-synuclein through the modulation of
the CNS myeloid cell activation state. This finding will




Animal experiments were approved by the Bavarian
authorities for animal experimentation (TS-2/14). All
experiments were performed following the European
(2010/63/EU) and National Institute of Health (NIH)
Guidelines for the Humane Treatment of Animals.
Transgenic mice (tg) over-expressing human WTS
under the mThy1 promoter (line 61; kindly provided
by Eliezer Masliah, USCD [22]) were crossed with
mice carrying a germline mutation, in which a large
portion of the coding region of the Rag2 gene is de-
leted, resulting in a lack of mature B and T lymphocytes
(termed Rag2−/−; [23]; kindly provided by Jürgen Witt-
mann, FAU Erlangen-Nürnberg). After several back cross-
ings, WTS+ Rag2+/+ mice were compared to the WTS+
Rag2−/− littermate controls. WTS− Rag2+/+ and WTS−
Rag2−/− mice were used as additional controls for the ef-
fect of α-synuclein over-expression where appropriate.
Polymerase chain reaction (PCR) was used to determine
the WTS and Rag2 genotype. Animals were kept in a 12-
hour (h) light/dark cycle and had access to food and water.
For dissection, 22–26-week-old animals were deeply anes-
thetized by CO2 inhalation and transcardially perfused
with ice-cold PBS. Brains were removed and either rapidly
stored at −80 °C for biochemical and RNA analyses or
post-fixed in 4 % PFA for 6 h on ice and subsequently
stored in 30 % sucrose in PBS at 4 °C until further
processing.
Immunohistochemistry
Frozen fixed brain hemispheres were cut into 40 μm
thick coronal sections using a sliding microtome (Leica
SM 2010R) and stored in cryo-protectant solution (25 %
ethylene glycol, 25 % glycerol in 0.1 M phosphate buffer,
pH 7.4) at −20 °C. Immunohistochemical staining of
free-floating sections was performed as published previ-
ously [24]. Briefly, sections were washed three times in
tris-buffered saline (TBS; pH 7.4) containing 0.05 %
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Triton X100 prior to a 30-minute (min) treatment with
citrate buffer (target retrieval solution, DAKO) at 80 °C.
After extensive washing, the sections were blocked for 1–
2 h in blocking solution (TBS, 3 % Donkey Serum, 0.03 %
Triton X100). Subsequently, sections were incubated with
primary antibody overnight at 4 °C using the following
primary antibodies: anti-human-α-synuclein (15G7, Enzo,
1:100), anti-CD3 (MCA1477, Serotec, 1:200), or anti-
CD19 (115501, BioLegend, 1:200), followed by incubation
with secondary antibodies according to the primary host
(anti-rat-horseradish peroxidase (HRP), Dianova) for 1 h
at room temperature (RT). Amplification of signal inten-
sity was achieved using avidin-biotin peroxidase complex
for 1 h (ABC Kit, Vector Laboratories), and signal
visualization was reached using 3,3-diaminobenzidine
(DAB) as the peroxidase substrate. All sections were
mounted in anatomical order on glass slides and cover-
slipped with NeoMount (Merck). For each staining, the
sections of all mice from one experiment were processed
simultaneously under the same conditions.
Immunofluorescence
After blocking as described above, the following primary
antibodies were applied to the free-floating sections for a
48 h incubation at 4 °C: anti-tyrosine hydroxylase (TH)
(MAB318, Millipore, 1:250), anti-ionized calcium-binding
adapter molecule (Iba) 1 (019-19741, WAKO, 1:500), and
anti-human-α-synuclein (15G7, Enzo, 1:100). Subse-
quently, secondary fluorochrome-coupled antibodies
(anti-mouse AlexaFluor 488, anti-rabbit Alexa Fluor 567,
anti-rat Alexa Fluor 488, all from Life Technologies,
1:500) were added to the sections for 1 h at RT followed
by 1 min staining with 4′,6-diamidin-2-phenylindol
(DAPI) (10 μg/ml, Life Technologies) to visualize cell
nuclei. All the sections were mounted in anatomical order
on glass slides and coverslipped with Aqua-Poly/Mount
(Polysciences). For each staining, the sections of all mice
from one experiment were processed simultaneously
under the same conditions.
Counting procedures
Quantification was achieved using a semiautomatic stereol-
ogy workstation microscope AxioImager M2 (Carl Zeiss)
with a Stereo Investigator 11 software (MicroBrightField) as
previously described [25]. All counting procedures were
performed on 40-μm thick coronal sections, and every sixth
section was analyzed for each experiment. Two different
brain regions were analyzed: the SN at the coordinates
anterior-posterior (ap) −2.58 to −3.78 mm and the striatum
ap 1.42 to −2.28 mm according to the Allen Mouse Brain
Atlas (http://mouse.brain-map.org/static/atlas). The re-
spective area was measured using the Stereo Investigator
11 software. All cells within a given area were counted
exhaustively in both regions using bright field (for DAB
immunostainings of α-synuclein and CD3) and fluor-
escence (for TH and Iba1 stainings) microscopy. The
investigator performing the quantification was blinded
to the genotype groups during the analysis.
Morphological characterization of CNS myeloid cells
The morphological characterization of CNS myeloid
cells was evaluated by defining four morphological types
based on the morphology of Iba1+ CNS myeloid cells.
These morphological phenotypes are associated with dif-
ferent states of CNS myeloid cell activation: resting,
primed, reactive, and activated [26–29]. Resting CNS
myeloid cells (type 1) displayed a small but defined cell
body and extensive numbers of branching processes.
Type 2 CNS myeloid cells, defined as primed CNS mye-
loid cells, remained highly ramified but represented a
distinctive ellipsoid-like soma. Both type 3 (reactive) and
type 4 (activated) CNS myeloid cells presented amoeboid-
shaped cell bodies, while the processes were less extensive
and shorter. While type 3 CNS myeloid cells displayed
few branches, which were generally longer than the cell
body diameter, type 4 CNS myeloid cells had no or few
unbranched processes seen to be within the length of
the cell body diameter [28, 29]. Three pictures visualiz-
ing Iba1+ cells in the SN region of five mice/group were
quantified according to the defined types. At least 30
CNS myeloid cells per mouse were traced, recon-
structed, and characterized.
Flow cytometry
Brains from 22- to 26-week-old animals were homoge-
nized using a 5-ml Glass Tissue Grinder (A. Harten-
stein). The homogenized solution was mixed with 100 %
Percoll solution (GE healthcare) to a final 70 % Percoll
solution and layered under a 30 % Percoll solution. After
30 min centrifugation at 500g without brake at RT, the
cells were isolated from the 30–70 % layer and washed
with PBS. Per staining, 100 000 cells were used. The
staining was performed in FACS-PBS (PBS, 2 % FCS,
5 mM EDTA) in the presence of the FcBlocker (Miltenyi
Biotec) using the following fluorescently labeled anti-
bodies: anti-CD4-PE, anti-CD8-APC, anti-CD11b-FITC,
and anti-CD45-APC (all from Miltenyi Biotec), for
15 min at RT in the dark. Samples were analyzed using a
Gallios flow cytometer (Beckman Coulter). Thirty thou-
sand events were recorded. Flow cytometry data were
analyzed using the FlowJo 8.5.3 software (FlowJo, LLC).
For viability testing, the Fixable Viability Dye eFluor® 780
(eBioscience) was used according to the manufacturer’s
instructions. The gating of the living cell population was
performed based on the live staining; dead cell popula-
tions were excluded. The total cell number was deter-
mined utilizing bead measurement (Beckman Coulter CC
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Size Standard L10), and the absolute cell numbers were
calculated according to the manufacturer’s instructions.
Real-time PCR
Frozen brain tissues were homogenized using an automated
TissueLyser LT (Qiagen) according to the manufacturer’s
instructions. Total RNA was extracted from homogenized
brain hemispheres using the RNeasy Mini kit (Qiagen) with
a DNA digestion step (RNase Free DNase Set; Qiagen) ac-
cording to the manufacturer’s instructions. Five hundred
nanograms of total RNA was reversely transcribed into
complementary DNA (cDNA) in 20 μl reaction solution
using the QuantiTect Reverse Transcription Kit (Qiagen)
according to the manufacturer’s instructions. One micro-
liter of cDNA was used per real-time PCR (RT-PCR) reac-
tion. RT-PCR was performed in duplicates in a final
volume of 20 μl using either 1× TaqMan Universal Master
Mix II, no UNG and 1× TaqMan Gene Expression Assay
for GAPDH, or 1× SYBR Green PCR Master Mix (all from
Applied Biosystems) and 200 nM of each primer for all
other transcripts in the ABI PRISM 7300 Sequence Detec-
tion System (Applied Biosystems). Forward and reverse
primer pairs (Sigma-Aldrich) for SYBR Green PCR are
shown in Table 1.
The RT-PCR program was as follows: 95 °C for
10 min, followed by 40 cycles at 95 °C for 15 s and 60 °C
for 1 min and 1 cycle at 95 °C for 15 s, 60 °C for 30 s
and 95 °C for 15 s. The specificity of the SYBR Green
detection was controlled by the occurrence of a single
peak in the dissociation curve. Relative quantification
was performed by calculating the difference in cross-
threshold values (ΔCt) of the gene of interest and a
mean of two housekeeping genes, GAPDH and HPRT1,
according to the formula 2−ΔCt.
Western blot analysis
Protein levels were assessed in brain lysates by western
blot analysis. Briefly, homogenized brains were lysed in
lysis buffer (2 % NP40, 150 mM NaCl, 50 mM HEPES,
10 % Glycerol, pH 8.5) and a cocktail of protease inhibi-
tors (complete Mini EDTA free, Roche). Protein concen-
trations of lysed samples were determined using the
bicinchoninic acid assay (Pierce BCA Protein Assay Kit,
Thermo Fisher Scientific). Equal amounts of total protein
(60 μg) were separated on 10 % SDS PAGE and trans-
ferred to nitrocellulose membranes (A. Hartenstein). Blots
were probed using primary antibodies: anti-CD206 (R&D
Systems, 1:2000), anti-ß-actin (Sigma-Aldrich, 1:3000),
anti-α-synuclein (BD Transduction Laboratories 1:2000),
and anti-GAPDH (FL-335, Santa Cruz Biotechnology,
1:1000), and HRP-conjugated anti-mouse, anti-rabbit, and
anti-goat secondary antibodies (Dianova, 1:20,000). For
visualization, the ECL SuperSignal West Pico or Femto
(Thermo Scientific) and ChemiDoc™ XRS+ System
(BioRad) were used. Signal intensity was measured by the
ImageLab software (version 5.2.1). The intensity of CD206
was normalized to that of actin.
BV2 co-culture
BV2 microglia (kindly provided by Johannes Schlachetzki,
FAU Erlangen-Nürnberg) were cultured in DMEM/F12 +
Glutamax medium supplemented with 100 U/ml penicil-
lin/streptomycin (both from Thermo Fisher Scientific)
and 10 % heat-inactivated FCS (1 h 56 °C). α-synuclein
aggregates were generated by incubating recombinant
human α-synuclein (100 μM in PBS; kindly provided by
Dr. Silvia Campioni, Swiss Federal Institute of Technology
Zurich, Switzerland) for 6 h at 37 °C with slight agitation
at 500 rpm, followed by 12 h shaking at 56 °C, 500 rpm.
Primary T and B lymphocytes were isolated from spleens
of WTS+ Rag2+/+ and WTS− Rag2+/+ mice. Briefly, iso-
lated spleens were homogenized in PBS/2 % FCS using a
70-μm strainer. After centrifugation of the homogenate
(5 min at 500 g), the pellet was incubated in erythrocyte
lysis buffer (0.15 M NH4Cl, 20 mM HEPES) for 5 min at
RT. Subsequently, the reaction was stopped with PBS/2 %
FCS, followed by centrifugation for 5 min at 500 g. The
resulting pellet was used for CD3 and CD19 MACS
Table 1 Primer sequences for RT-PCR analysis
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sorting (CD3ε MicroBead Kit, mouse; CD19 MicroBead
Kit, mouse; both Miltenyi Biotec) according to the manu-
facturer’s instructions. Isolated CD3+ T lymphocytes were
activated (Dynabeads® Mouse T-Activator CD3/CD28;
Thermo Fischer Scientific) and directly used for co-
culture with BV2 cells. B lymphocytes were activated with
lipopolysaccharide (LPS, 10 μg/ml, Sigma-Aldrich) for 2 h
prior co-culture with BV2 cells. All co-cultures were per-
formed in a ratio of 1:10 (lymphocytes/BV2 cells) in the
presence of 200 nM aggregated α-synuclein. After 24 h,
the co-cultured cells were fixed and analyzed for Iba1+
and α-synuclein+ by immunofluorescence staining (Iba1,
WAKO, 1:300; α-synuclein 15G7, Enzo, 1:200). For evalu-
ation, the LSM 780 confocal laser scanning microscope
(×63 PLAPOoil objective, pinhole 1 airy unit; Carl Zeiss)
was employed, and cells were quantified using ImageJ
software. The phagocytosis level was determined as the
frequency of Iba1 and α-synuclein double-positive cells
over the total Iba1+ cell amount in the co-culture. Three
independent experiments were performed.
Statistical analysis
Each in vivo experiment was performed with ten mice
for stereology experiments and three to five mice/group
for flow cytometry, immunofluorescence staining, and
gene and protein expression as well as for BV2 co-
culture experiments. Differences between the two groups
were analyzed using the two-tailed Student’s t test.
When more than two groups were compared, differences
were analyzed with a one-way ANOVA followed by
Tukey post hoc test. In all analyses, p values of less than
0.05 were considered significant. All statistical tests were
conducted with GraphPad Prism 5 software (GraphPad
Software, Inc.).
Results
The presence of lymphocytes exacerbates α -synuclein
aggregates in the SN and striatum
We addressed the role of adaptive immune cells in synu-
cleinopathies. Therefore, mice over-expressing human
WTS (WTS+) [22] were crossed with mice lacking mature
T and B lymphocytes (Rag2−/−) [23]. Brain tissues of WTS+
Rag2+/+ and WTS+ Rag2−/− mice (n = 10) were stained for
α-synuclein. α-synuclein aggregates, defined as distinct
brown spots of at least 3 μm in diameter (Fig. 1a, b,
arrows), were counted stereologically in the PD-associated
regions SN and striatum. In WTS+ Rag2+/+ and WTS+
Rag2−/− mice, α-synuclein aggregates were frequently de-
tected both in the SN and striatum (Fig. 1a, b). Interest-
ingly, in mice with intact lymphocytes (WTS+ Rag2+/+),
significantly more α-synuclein aggregates were determined
(26 ± 4 aggregates/100,000 μm2 SN) as compared to WTS+
Rag2−/− mice lacking lymphocytes (12 ± 5 aggregates/
100,000 μm2 SN) (Fig. 1c, d). In line, proteinase K (PK)
treatment indicated significantly increased amounts of
insoluble PK-resistant α-synuclein aggregates in the SN
and striatum in the presence of mature lymphocytes in
WTS+ Rag2+/+ mice (8 ± 1 aggregates/100,000 μm2 SN)
compared to WTS+ Rag2−/− mice (6 ± 1 aggregates/
100,000 μm2 SN) (Fig. 1c, d). Control mice (WTS−
Rag2+/+ and WTS− Rag2−/− (n = 3 per group)) did not
show any α-synuclein aggregates (Fig. 1a–d). Since α-
synuclein pathology in the SN was found to be more
prominent than in the striatum, further analyses fo-
cused on the SN. Confirming the immunohistochemical
analysis, western blot analysis also showed lower
amounts of α-synuclein protein in absence of lympho-
cytes (Fig. 1e).
To analyze, whether lymphocytes affect the number of
dopaminergic neurons, we stained for TH+ neurons in
the SN (Fig. 1e). No differences in the number of TH+
neurons in WTS+ Rag2+/+ mice (2 927 ± 290 TH+ neu-
rons/SN) compared to WTS+ Rag2−/− mice (2 989 ± 306
TH+ neurons/SN) were observed (Fig. 1f ). In accordance
with previous publications [22, 30], there was no signifi-
cant reduction of TH+ neurons in the SN between WTS
tg (WTS+ Rag2+/+, WTS+ Rag2−/−) and non-tg (WTS−
Rag2+/+, WTS− Rag2−/−) mice (data not shown).
Together, our data indicate that lymphocytes exacerbate
α-synuclein aggregation in a progressive synucleinopathy
model.
T lymphocytes infiltrate the brain of WTS+ Rag2+/+ mice
A previous study emphasized a crucial role of T lympho-
cytes rather than B cells in mediating pathology in the
MPTP mouse model of PD [18]. To analyze the presence
of T and B lymphocytes in the CNS in WTS+ and WTS−
mice, we investigated lymphocyte infiltration into the
brain tissue by immunohistochemical staining for the T
lymphocyte marker CD3 and the B lymphocyte marker
CD19. Positively stained CD3 cells were found in low
numbers and broadly distributed in the midbrain of
WTS+ Rag2+/+ mice but not in mice of WTS+ Rag2−/−
nor WTS− mice (Fig. 2a, b). No positive staining for
CD19 was detected in the midbrain of WTS+ mice
(Additional file 1). Further analysis of the infiltrating T
lymphocyte population was performed in whole-brain
homogenates. Flow cytometry revealed the presence of
both CD4+ (helper) and CD8+ (cytotoxic) T lymphocytes
in brains of WTS+ Rag2+/+, but not in brains of WTS+
Rag2−/− or in WTS− mice (Fig. 2c–e).
Infiltrating T lymphocytes are associated with a pro-
inflammatory M1 phenotype
To analyze how infiltrating T lymphocytes aggravate
α-synuclein aggregation, we examined if infiltrating T
lymphocytes influence the CNS innate immune cells.
We investigated the possible effect of T lymphocytes
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on CNS myeloid cells (microglia and brain macro-
phages), which are responsible for sensing, clearing,
and performing the primary immune responses in the
CNS environment. To quantify CNS myeloid cells, we
first counted Iba1+ cells in the SN and did not find
differences in the number of Iba1+ cells or gene
expression of CD11b between WTS+ Rag2+/+ and
WTS+ Rag2−/− mice (Fig. 3a–c). We also did not find
any significant differences in the morphology of Iba1+
cells between WTS+ Rag2+/+ and WTS+ Rag2−/− mice
(see Additional file 2: evaluation of microglia morph-
ologies for resting, primed, reactive, and activated
microglia). Flow cytometry determined no difference
in the frequencies of CD11bhiCD45lo cells as marker for
resident myeloid cells (Fig. 3d). Interestingly, we found
elevated frequencies of CD11b+CD45hi cells representing
newly infiltrated myeloid cells [31] in WTS+ Rag2−/− mice
compared to WTS+ Rag2+/+ (Fig. 3e, f ). These data indi-
cate that a lack of mature T lymphocytes led to increased
infiltration of peripheral myeloid cells in synucleinopa-
thies, while the frequencies of resident myeloid cells
remained unchanged.
Activated CNS myeloid cells are a characteristic fea-
ture of synucleinopathies [16, 32]. We further analyzed
whether T lymphocytes affect the phenotype of activated
CNS myeloid cells. We therefore performed gene
Fig. 1 Increased numbers of α-synuclein in the presence of lymphocytes. a, b Representative bright field pictures of the a substantia nigra and
b striatum show α-synuclein aggregates in WTS+ Rag2+/+ and WTS+ Rag2−/− but not in WTS− mouse brains. α-synuclein was stained in the brain
tissue of 22–26-week-old mice using anti-α-synuclein (15G7) antibody. Scale bars 100 μm. Arrows indicate α-synuclein aggregates determined as
brown spots of at least 3 μm in diameter and are shown by arrows. c, d Significantly reduced numbers of α-synuclein aggregates were found in
WTS+ Rag2−/− compared to WTS+ Rag2+/+ mice in both the substantia nigra and striatum without and with proteinase K (PK) treatment. Control
mice (WTS−) did not show any aggregates. T-test **p < 0.01, ***p < 0.001. e The protein level of α-synuclein was determined by western blotting
indicating increased amount of α-synuclein protein in WTS+ Rag2+/+ mice compared to WTS+ Rag2−/− mice (n = 3 per group). f WTS+ Rag2+/+ and
WTS+ Rag2−/− brains were stained for the dopaminergic neuronal marker tyrosine hydroxylase (TH), and representative pictures of the substantia nigra
are shown. g No significant difference in the number of TH+ neurons could be detected by stereological quantification in the SN of WTS+ Rag2+/+
compared to WTS+ Rag2−/− mice. Scale bar 50 μm. c, d, g Data from nine to ten (five for WTS−) mice/group are shown
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expression analysis of characteristic M1 and M2 pheno-
type markers in the whole-brain lysates of WTS+ and
WTS− mice and normalized the expression in WTS+
Rag2+/+ and WTS+ Rag2−/− mice to a homeostatic
expression of these genes in control WTS− Rag2+/+ and
WTS− Rag2−/− mice. We found a significant upregula-
tion of M1-associated pro-inflammatory genes including
TNF-α and IL-1β and a trend towards more ICAM1 in
WTS+ Rag2+/+ compared to WTS+ Rag2−/− mice (Fig. 4a,
left panel). In contrast, mice lacking lymphocytes (WTS+
Rag2−/−) showed significantly upregulated expression
levels of the M2-associated anti-inflammatory genes
Arg1 and Lgals3 and a tendency for CD200r level com-
pared to WTS+ Rag2+/+ (Fig. 4a, right panel). Further we
analyzed protein expression of CD206 (mannose recep-
tor), which is a phagocytic receptor predominantly
Fig. 2 CD3+ lymphocytes infiltrate the midbrain of WTS+ Rag2+/+ mice. a WTS+ Rag2+/+ and WTS+ Rag2−/− as well as WTS− brains were stained
for the T lymphocyte marker CD3 as shown in representative bright field pictures of the midbrain and the quantification in b. Infiltrating CD3+
lymphocytes, labeled with asterisks, do not co-localize with blood vessels (indicated by the dotted lines). CD3+ cells were only present in WTS+
Rag2+/+ mice, but not in WTS+ Rag2−/− or WTS− mice. Scale bar 50 μm. b Data from five mice/group are shown. c–e Flow cytometry analysis of
the brain tissues was performed to confirm the presence and to analyze the subsets of T lymphocytes in WTS+ Rag2+/+ mice. c 30,000 events
were recorded, and a total population was defined in the forward/side scatter, excluding dead cells, which were identified by utilizing a live-dead
staining, for further gating strategies (upper histogram). The CD4+ (CD11b−) population representing CD4+ T lymphocytes and distinguished from
CD4 low positive CD11b+ microglia population is shown in a representative dot plot (lower histogram). Representative scatter and dot plot are
shown from brain tissue of a WTS+ Rag2+/+ mouse. d Gated populations for the T lymphocyte subset markers CD4 (T helper cell) and CD8
(cytotoxic T cell) are visualized in representative dot plots, and total cell numbers of CD4 and CD8 T cells per group ± SEM are shown in e, which were
determined based on bead measurement and calculation of the total cell number. Significantly more CD4+ and CD8+ T cells are present in WTS+ Rag2
+/+ compared to WTS+ Rag2−/− and WTS− mouse brain tissues. Data from five mice/group are shown. T-test, *p < 0.05, ***p < 0.001
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associated with M2 phenotype, in brain lysates of WTS+
Rag2+/+ and WTS+ Rag2−/− mice. As shown in Fig. 4b,
we could detect significantly increased levels of CD206
in WTS+ Rag2−/− brains compared to WTS+ Rag2+/+
brains, suggesting the prevalence of the M2 phenotype
in WTS+ Rag2−/− mice. Thus, in the presence of lym-
phocytes (WTS+ Rag2+/+), CNS myeloid cells adopt a
characteristic M1 phenotype, while in the absence of
lymphocytes (WTS+ Rag2−/−), an M2 phenotype is more
predominant.
BV2 microglia show increased phagocytosis of α-synuclein
in the absence of T lymphocytes in vitro
Since the M2 anti-inflammatory phenotype is linked
with higher phagocytic activity compared to the M1
pro-inflammatory phenotype, the effect of T and B
Fig. 3 Increased presence of infiltrating myeloid cells in brains of WTS+ Rag2−/− mice. a Representative fluorescence pictures of the substantia
nigra (SN) of WTS+ Rag2+/+ and WTS+ Rag2−/− mice stained for TH+ neurons to visualize the SN (upper panel) and for Iba1 to visualize CNS myeloid
cells in the SN (lower panel). Scale bars 50 μm. The total number of b Iba1+ myeloid cells in the SN, c CD11b mRNA expression measured by qRT-PCR
and d CD11b+ CD45lo cell frequency measured by flow cytometry (total of 30,000 recorded events, total brain cell population was defined as shown in
Fig. 2c, defined as shown in the representative dot plots in e, red box) were unchanged between WTS+ Rag2+/+ and WTS+ Rag2−/− mouse brain tissues.
e, f A significant increase in infiltrating myeloid cells defined as CD11b+ CD45hi population (green box in E) was found in WTS+ Rag2−/− compared to
WTS+ Rag2+/+ brains in flow cytometry analysis. Data from four to five mice/group are shown as means ± SEM. T-test, **p < 0.01
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lymphocytes on the phagocytic activity of microglia
cells was further investigated. We performed an in vitro
experiment by co-culturing BV2 microglia cells with α-
synuclein aggregates (Fig. 5a) and activated T or B lym-
phocytes isolated from spleens of WTS+ Rag2+/+ or
WTS− Rag2+/+ mice. In the presence of T lymphocytes
derived from WTS+ Rag2+/+ mice, less α-synuclein ag-
gregates were taken up by BV2 cells (Fig. 5c). Similarly,
T lymphocytes from WTS− Rag2+/+ mice also reduced
α-synuclein uptake of BV2 cells (Fig. 5d), demonstrat-
ing that the inhibitory effect of T lymphocytes on BV2
phagocytic capacity is rather a specific T cell function.
The presence of α -synuclein in T lymphocytes from
WTS over-expressing mice did not alter the result. The
addition of B lymphocytes did not have any effect on
the uptake of α-synuclein aggregates by BV2 cells inde-
pendently of their origin (either isolated from WTS+
Rag2+/+ or WTS− Rag2+/+ mice) (Fig. 5c). These results
show that T lymphocytes, but not B lymphocytes, in
the presence of α-synuclein aggregates, reduce the
phagocytic activity of microglia. Together, our data sug-
gest a crucial role of T lymphocytes in modulating mye-
loid cell activation towards a pro-inflammatory M1
phenotype in synucleinopathy (Fig. 6).
Discussion
While T lymphocytes were recently shown to play an
important role for TH+ cell loss in a toxin-induced PD
mouse model [18, 33], the effect of T lymphocytes for
progressive synucleinopathies, and the mechanism of
their action remain elusive. In this study, we describe
the impact of T lymphocytes in a WTS over-expression
synucleinopathy model. The presence of lymphocytes
was associated with an increased number of α-synuclein
aggregates in the SN and striatum of WTS+ Rag2+/+
mice and CD3+ T lymphocytes. No CD19+ B cells were
found in the midbrain of these mice. In the absence of
lymphocytes, increased amounts of infiltrated myeloid
cells (CD11b+ CD45hi) were detected, which, together
with resident microglia, could contribute to the preva-
lence of the M2 phenotype. Higher expression of the
phagocytic receptor CD206 in WTS+ Rag2−/− mouse
brains, compared to that in WTS+ Rag2+/+ mice, might
indicate increased phagocytosis activity and improved
clearance of α-synuclein aggregates in the absence of
lymphocytes, supporting the M2 phenotype. Moreover,
primary T but not B lymphocytes inhibited the uptake of
α-synuclein aggregates by BV2 microglia cells in vitro,
indicating a lower phagocytic capacity of CNS myeloid
cells in the presence of T cells. Thus, we suggest that
T lymphocytes contribute to the progression of synu-
cleinopathies by modulating the myeloid phagocytosis
activity (Fig. 6).
Increased α-synuclein pathology in the SN and striatum in
the presence of lymphocytes
α-synuclein aggregation in the mThy1 WTS mouse model
is present in various brain regions including the thalamus,
Fig. 4 Infiltrating T lymphocytes are associated with a M1 myeloid phenotype. a Gene expression of characteristic M1 markers (TNF-α, IL-1β,
ICAM1) measured by qRT-PCR shows their upregulation in WTS+ Rag2+/+ mice compared to WTS+ Rag2−/− mice, while genes associated with an
anti-inflammatory M2 phenotype (Arg1, Lgals3, CD200r) are upregulated in WTS+ Rag2−/− compared to WTS+ Rag2+/+ mice. The gene expression
values in WTS+ mice were normalized to the respective gene expression levels in WTS− mice. RNA was extracted from the whole-brain lysates.
Data are shown as mean of five mice/group ± SEM. b The phagocytic receptor, CD206, is increased in brain tissue of WTS+ Rag2−/− compared to
WTS+ Rag2+/+ mice on protein level as shown by western blot analysis with three mice/group (upper panel) and by densitometric quantification
(lower panel) Data are presented as mean ± SEM
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basal ganglia, brainstem, SN, and striatum [22]. We ana-
lyzed α-synuclein aggregates in the SN and striatum of
WTS+ Rag2+/+ and WTS+ Rag2−/− mice. We found that
aggregate numbers were significantly decreased in the ab-
sence of lymphocytes. Accordingly, a previous study using
an acute MPTP mouse model of PD [18] demonstrated a
critical contribution of T lymphocytes in dopaminergic
cell loss in the SN. Another study showed an early infiltra-
tion of CD4 and CD8 T lymphocytes in the AAV-based
rat model of PD, over-expressing high levels of human
α-synuclein causing neuronal cell death [29]. In accord-
ance with our data, the mThy1 WTS model was previ-
ously characterized by the absence of TH+ neuronal
loss [22, 30] or motor deficits associated with DA neur-
onal loss [34]. A property of most current PD genetic
mouse models is the lack of dopaminergic loss. Loss of
TH+ neurons is thought to be a late pathological hall-
mark in PD, while α-synuclein aggregation starts earlier
[1]. Thus, using a model of α-synuclein pathology
rather than a massive TH+ loss may enable investiga-
tion of early mechanisms of synucleinopathy.
Taking together, we demonstrated that lymphocytes
enhance α-synuclein PD-related pathology as shown by
the presence of more α-synuclein aggregates in the SN
and striatum. The present study is demonstrating an
association between the presence of T lymphocytes and
progressively developing α-synuclein pathology.
CD3+ lymphocytes infiltrate the CNS in the
synucleinopathy model
A more detailed analysis of the adaptive immune cells in
WTS+ Rag2+/+ mice revealed that CD3+ T but not CD19+
B lymphocytes infiltrated the midbrain of these mice, sug-
gesting that specifically T lymphocytes influence α-
synuclein pathology. Another study using this mThy1
WTS mouse model did not find any increase in the CD8+
T lymphocyte infiltration in the striatum [35], possibly
due to the brain region specificity of lymphocyte infiltra-
tion or due to a preferential CD4 T cell infiltration into
the midbrain and striatum. In accordance with our data,
Brochard and colleagues could show that CD4+ T cells ra-
ther than B lymphocytes were critically involved in the
progression of disease pathology and were responsible for
the elevated neurotoxic effect on DA neurons [18]. Their
study also described the presence of T lymphocytes in hu-
man post mortem brains of PD patients, strongly empha-
sizing a crucial role of T cells in the pathogenesis of PD.
Besides, earlier studies have shown alterations in lympho-
cyte populations in PD peripheral blood compared to con-
trols [17, 21] and a significant increase of CD4 and CD8 T
cells in the blood of mThy1 WTS mice [35]. These find-
ings further stress the importance of peripheral lympho-
cytes in PD. In addition, in PD models damage of the
blood brain barrier was shown [36, 37], allowing the infil-
tration of peripheral immune cells.
Fig. 5 T lymphocytes reduce phagocytosis activity of microglia in vitro. a BV2 microglia cells were co-cultivated with aggregated α-synuclein (200nM)
in absence or presence of T or B lymphocytes at the 10:1 ratio (BV2/lymphocytes) for 24 h. b Recombinant human α-synuclein was aggregated in vitro
(electron microscopy picture, scale bar 0.2 μm). c α-synuclein uptake was quantified as percentage of Iba1 and α-synuclein double-positive cells within
total Iba1+ population and normalized to a control uptake level in the absence of lymphocytes. α-synuclein uptake was significantly decreased in the
presence of T cells, but not B cells, compared to control condition. d Co-culture of BV2 cells under the same conditions as in c with T lymphocytes
isolated from WTS− mice did not alter the α-synuclein uptake compared to the co-culture with T lymphocytes from WTS+ mice. Scale bar 20 μm.
T-test, *p < 0.05, ***p < 0.001
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Increased macrophage infiltration in the CNS of WTS tg
mice in the absence of lymphocytes
To investigate the mechanism by which infiltrating CD3+
T lymphocytes affect the disease pathology, we examined
innate immune cells. Lymphocytes did not influence the
quantity of resident myeloid cells as determined by the
numbers of Iba1+ and frequencies of CD11b+CD45lo cells.
In addition, we could not detect any differences in the
morphology of myeloid cells in the brains of WTS+ mice
with or without lymphocytes. This suggests that CNS
myeloid cells are activated in both WTS+ Rag2+/+ and
WTS+ Rag2−/− mice. However, activated CNS myeloid
cells can be further distinguished into M1 and M2 cur-
rently merely using gene expression analysis of pro- and
anti-inflammatory markers. Thus, although we did not ob-
serve morphological differences, it might be possible that
the activated CNS myeloid cells in our model perform dif-
ferent functions in presence or absence of T lymphocytes.
Interestingly, in the AAV-based rat model of PD exhibit-
ing a profound neurodegeneration and cell death, the sus-
tained CNS myeloid cell activation was associated with a
prominent T lymphocyte infiltration into the SN [29].
In contrast, increased frequencies of CD11+CD45hi
cells, a characteristic expression pattern of peripheral
myeloid cells [31], were detected in the CNS of WTS+
Rag2−/− mice. These findings suggest that there is more
intense infiltration of peripheral myeloid cells in WTS+
Rag2−/− mice. Infiltration of peripheral myeloid cells was
also described for other neurodegenerative diseases like
Alzheimer’s disease [38, 39]. Here, we show that this
infiltration might be strongly dependent on lymphocytes.
Importantly, infiltrating myeloid cells are suggested to
primarily eliminate protein aggregates in the brain [40].
In our model, CNS-infiltrated myeloid cells with in-
creased phagocytosis activity [41] could result in a better
clearance of α-synuclein aggregates, thereby decreasing
pathology in WTS+ Rag2−/− mice.
The M1 phenotype is associated with the presence of T
lymphocytes
We could show that, in the presence of T lympho-
cytes in WTS+ Rag2+/+ mice, activated CNS myeloid
cells had a M1 phenotype, due to increased expres-
sion of pro-inflammatory cytokines like TNF-α and IL-1β
and reduced protein levels of the phagocytic receptor
CD206. In contrast, the lack of lymphocytes in WTS+
Rag2−/− mice correlated with increased expression of
genes associated with the M2 phenotype and higher ex-
pression of CD206, suggesting stronger phagocytic activity
in the CNS in these mice. Increased phagocytosis of M2
myeloid cells [8, 9, 32, 42] leading to more efficient clear-
ance might be responsible for the reduced numbers of
Fig. 6 Model of the potential contribution of T lymphocytes in synucleinopathies. In the synucleinopathy, T lymphocytes infiltrate the CNS and
lead to an increase of the M1 phenotype of activated myeloid cells. The phagocytic activity of the CNS myeloid cells is thereby reduced leading
to the increased presence of α-synuclein aggregates
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α-synuclein aggregates found in WTS+ Rag2−/− mice. This
suggests that M2 myeloid cells are able to reduce
α-synuclein pathology and thus could slow down
disease progression. On the other hand, if infiltrating T
lymphocytes modulate the myeloid cell activation towards
a pro-inflammatory M1 phenotype with reduced phago-
cytic activity, it could explain higher α-synuclein aggrega-
tion in WTS+ Rag2+/+ mice. Consistent with this finding,
α-synuclein uptake by BV2 microglia in vitro was reduced
in the presence of T lymphocytes independent of their
origin, further supporting our results that infiltrating T
lymphocytes facilitate the switch from M2 into M1 pheno-
type in synucleinopathy. On the other hand, α-synuclein
uptake by BV2 microglia in vitro was not influenced by
the presence or absence of B lymphocytes. Although BV2
cells are frequently used as in vitro cell model to study
microglia function [43], a recent study demonstrated the
limits of BV2 cells when compared to primary microglia
[44]. Therefore, further experiments using primary
isolated microglia from mouse brain tissue will be
important to study T lymphocyte-dependent α-synuclein
uptake in microglia/CNS myeloid cells.
The destructive role of the M1 myeloid cell activity in
neurodegenerative diseases was described recently by
increased cell death of spinal cord motor neurons in condi-
tions of downregulated M2 population in spinal cord injury
[12] and by a more progressive experimental autoimmune
encephalomyelitis, the model of MS, under dominating
M1 state [45]. Thus, pharmacologically targeting specific
myeloid cell activation states might open additional, more
effective treatment options for neurodegenerative diseases
including synucleinopathies. Moreover, further investiga-
tion of the mechanisms, by which T cells might modulate
CNS myeloid cell activation, would open additional
possibilities for new treatment strategies.
Conclusions
In conclusion, using a progressive synucleinopathy model,
we demonstrate a critical role of T lymphocytes in enhan-
cing the number of α-synuclein aggregates by modulation
of myeloid cell activation. The prevalence of the M1 pheno-
type and impaired phagocytic activity in the presence of T
lymphocytes result in reduced clearance of α-synuclein
aggregates, thereby enhancing progression of synucleinopa-
thy. Thus, blocking M1 activation or an infiltration of T
lymphocytes might slow disease progression and could be
an option for potential pharmaceutical intervention.
Additional files
Additional file 1: B lymphocytes do not infiltrate the midbrain of WTS+
Rag2+/+ mice. (A) WTS+ Rag2+/+ and WTS+ Rag2−/− brains were stained
for the B lymphocyte marker CD19. Representative bright field pictures of
the midbrain regions show that no positive staining could be detected.
(B) To proof the functionality of the applied antibody, spleen of WTS+
Rag2+/+ mice were stained with the same anti-CD 19 antibody and
strong positive staining could be detected. Scale bar 50 μm. (TIF 992 kb)
Additional file 2: No morphological differences were detected in CNS
myeloid cells of WTS+ Rag2+/+ and WTS+ Rag2−/− mice. (A) Representative
pictures of four distinct CNS myeloid cells morphological types analyzed
associated with the respective activation state of the CNS myeloid cells:
type 1 CNS myeloid cells were defined as resting CNS myeloid cells, type 2
as primed, type 3 as reactive and type 4 as activated. (B) Quantification of
the defined CNS myeloid cells types in the SN of WTS+ Rag2+/+ and WTS+
Rag2−/−. Scale bar 20μm. (TIF 1856 kb)
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